| Literature DB >> 34657245 |
Paul E Gray1,2,3, Bethany A Pillay4,5, Stuart G Tangye4,5,1, Jin Yan Yap4,1, William A Figgett4, John Reeves4,5, Sarah K Kummerfeld4, Jennifer Stoddard6, Gulbu Uzel7, Huie Jing7, Helen C Su7, Dianne E Campbell8,9, Anna Sullivan1,10, Leslie Burnett4,5,1,9, Jane Peake1,10, Cindy S Ma11,12,13.
Abstract
Rare, biallelic loss-of-function mutations in DOCK8 result in a combined immune deficiency characterized by severe and recurrent cutaneous infections, eczema, allergies, and susceptibility to malignancy, as well as impaired humoral and cellular immunity and hyper-IgE. The advent of next-generation sequencing technologies has enabled the rapid molecular diagnosis of rare monogenic diseases, including inborn errors of immunity. These advances have resulted in the implementation of gene-guided treatments, such as hematopoietic stem cell transplant for DOCK8 deficiency. However, putative disease-causing variants revealed by next-generation sequencing need rigorous validation to demonstrate pathogenicity. Here, we report the eventual diagnosis of DOCK8 deficiency in a consanguineous family due to a novel homozygous intronic deletion variant that caused aberrant exon splicing and subsequent loss of expression of DOCK8 protein. Remarkably, the causative variant was not initially detected by clinical whole-genome sequencing but was subsequently identified and validated by combining advanced genomic analysis, RNA-seq, and flow cytometry. This case highlights the need to adopt multipronged confirmatory approaches to definitively solve complex genetic cases that result from variants outside protein-coding exons and conventional splice sites.Entities:
Keywords: DOCK8 deficiency; RNA sequencing; flow cytometry; intronic variant; whole-genome sequencing
Mesh:
Substances:
Year: 2021 PMID: 34657245 DOI: 10.1007/s10875-021-01152-x
Source DB: PubMed Journal: J Clin Immunol ISSN: 0271-9142 Impact factor: 8.542